Semaglutide Wegovy®

(Commercial Product) Prefilled Pen Solution for Injection

0.25 mg / dose  |  0.5 mg / dose  |  1 mg / dose  |  1.7 mg / dose  |  2.4 mg / dose

Ready to prescribe?
Disclaimer: Images are for reference only; actual products may vary.

Product Overview

Semaglutide Injectable Description1-3

Semaglutide is a synthetic glucagon-like peptide-1 receptor agonist (GLP-1 RA) that functions as an incretin mimetic. Incretins are hormones released from the gastrointestinal tract into the systemic circulation that help support glycemic regulation. This medication is used for the following indications:

For the management of obesity and for long-term weight management when used alongside a reduced-calorie diet and increased physical activity. It is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in: adults who are obese or overweight.

Mechanism of Action 1-3

Semaglutide is an incretin mimetic that works on the glucagon-like peptide-1 (GLP-1) receptor by binding and activating the GLP-1 receptor. It has 94% sequence homology to human GLP-1. GLP-1 medications regulate glucose metabolism after oral consumption of carbohydrates and fats. The drug increases insulin secretion by glucose-dependent insulin synthesis and in vivo secretion of insulin from pancreatic beta cells in the presence of elevated glucose levels. It also suppresses glucagon secretion, slows gastric emptying, reduces food intake, and promotes beta-cell proliferation.

Adverse Reactions1-3

Common 

  • Gastrointestinal: Nausea, vomiting, diarrhea, constipation, dyspepsia
  • Headache, dizziness, and injection site reactions

Contraindications & Precautions 1-3

Contraindications:

  • Hypersensitivity to liraglutide or its components
  • In people with a personal or family history of medullary thyroid carcinoma (MTC) or in people with multiple endocrine neoplasia syndrome type 2
  • In patients who are pregnant

Precautions:

  • In patients with a history of pancreatitis and gallbladder disease
  • In patients with renal and hepatic impairment

Refrigerate at 2–8°C (36–46°F) before and during use. Do not freeze. Protect from light and excessive heat.

  1. Semaglutide (Wegovy) Prescribing Information Novo Nordisk accessdata.fda.gov/drugsatfda_docs/label/2023/215256s007lbl.pdf. Revised July 2023. Accessed February 5, 2026
  2. Clinical Pharmacology semaglutide clinical monograph 2025 https://www.clinicalkey.com/pharmacology/
  3. Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol (Lausanne). 2019 Apr 12;10:155.

WPPL operates as a 503A compounding pharmacy and prepares individualized prescription medications pursuant to provider direction. Compounded preparations are not reviewed, tested, or approved by the FDA.

This listing also includes commercially manufactured products for convenience; these items are not compounded by our pharmacy and are sold as provided by their manufacturers. Actual products in stock at time of dispensing may vary due to supply chain variability. Any statements regarding non-compounded products are manufacturer-supplied, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease. WPPL does not verify or endorse any therapeutic claims made by manufacturers. Please refer to original labeling for complete product information.

EXPLORE MORE

Related Medications

Licensed to ship across the U.S.

Your orders arrive promptly and privately, delivered directly to your door.

Providers: Let’s Partner for Better Patient Care

If you are a physician, clinic, or practice seeking a dependable Compounding Pharmacy partner, WP Pharma Labs is here to help. With dedicated account setup, streamlined ordering and responsive service, we support your therapeutic goals with specialized compounds designed for your patients.

To check product availability, check on the status of an existing order, request refills:
orders@wppharmalabs.com

New providers setup / update an existing account:
newaccounts@wppharmalabs.com